Skip to content

Effect of Bronchom in the Management of Allergic Rhinitis

Effectiveness of the Ayurvedic Formulation Bronchom in the Management of Allergic Rhinitis: Prospective, Open label, Single arm, observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089640
Enrollment
59
Registered
2025-06-26
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Patanjali Research Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects diagnosed as allergic rhinitis based on reported symptoms. Subjects will have a total nasal symptom score (TNSS) of more than equal to 3. Subjects must provide informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: Subjects with a history of asthma (other than mild intermittent) and taking asthma medications or nasal disorders (such as deviated septum nasal polyposis or chronic rhinosinusitis) acute or significant sinusitis and those with an existing serious medical condition (eg severe emphysema). Subjects receiving allergen immunotherapy acute or chronic infections or on prolonged (more than equal to 6 weeks) medication with corticosteroids anticholinergics or any other drugs that may have an influence on the outcome of the study. Pregnant or lactating individuals due to potential risks to the fetus or infant from Ayurvedic treatments.

Design outcomes

Primary

MeasureTime frame
Assessing the mean change in Total Nasal Symptom Score (TNSS)Timepoint: baseline to Day 14 and Day 28.

Secondary

MeasureTime frame
Assessment of the total RQLQ scoreTimepoint: baseline to Day 14 and Day 28.;Assessing domain-wise changes in RQLQ scores to determine the impact on specific aspects of quality of life.Timepoint: baseline to Day 14 and Day 28.;Assessing the percentage of symptom-free days relative to the total number of days during the study periodTimepoint: baseline to Day 14 and Day 28.

Countries

India

Contacts

Public ContactDr Kumud Chauhan

Patanjali Yoggram Yog Naturopathy Panchkarma Treatment and Research Centre

kumudchauhan3@gmail.com7456938311

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026